Oncology companies want their brands to have the broadest possible indications, but prominent 1L trial failures may lead to persistent doubts.

We all want to win pitches, so we should start by avoiding common mistakes that can derail our presentations and make the process harder

Waiting for your trial to read out before beginning launch planning? Consider what you might be missing out on before you go that route.

The life sciences industry faces some headwinds in 2023, but some encouraging trends and opportunities can help you overcome them.